Waters Corporation and BD (Becton, Dickinson and Company) announced plans to merge BD's Biosciences & Diagnostic Solutions business with Waters.
The transaction was valued at approximately $17.5 billion, according to a release. Goals of the merger:
- To integrate “complementary technologies to serve high-volume testing in attractive and regulated end-markets.”
- To increase revenue.
- To aid “Waters' expansion into multiple high-growth adjacent end-markets.”
- To “unlock new ways to separate large molecules and to drive growth in biologics and novel modalities with next-generation consumables.”
